PreCision Dermatology Acquires Assets of Triax Pharmaceuticals

April 30, 2012

PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescription dermatology subsidiary of PreCision Dermatology, will market the newly acquired products. Jeffrey Nugent leads preCision Dermatology, and Jeffrey Wayne leads Onset Dermatologics. The acquisition allows for the barrier repair product HylatopicPlus and Locoid to aid in treating atopic dermatitis, and “Minocin and Tretin-X are an excellent fit with our existing BenzEFoam acne franchise,” said Mr. Wayne.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free